Differences in E-Cadherin and Syndecan-1 Expression in Different Types of Ameloblastomas

Figure 1

Intraluminal/luminal unicystic ameloblastomas in which the expression of E-cadherin was evaluated using ImmunoMembrane software. (a) Negative (or < 10%) immunostaining, intensity (0); (b) positive (≥10%) immunostaining, intensity (1+); (c) positive immunostaining, intensity (2+); (d) positive immunostaining, intensity (3+); (e) group control for E-cadherin expression in oral mucosa, positive immunostaining, intensity (3+); (f) group control for syndecan-1 expression in oral mucosa, positive immunostaining, intensity (3+).

(a)

(b)

(c)

(d)

(e)

(f)